Curiteva marked the milestone of over 5,000 levels successfully treated using the Inspire Cervical implant, an increase from 2,000 procedures performed as of the end of 2024, and just two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D-printed trabecular PEEK implant.
Engineered with Curiteva’s proprietary Fused Filament Fabrication 3D printers, Inspire implants feature a fully interconnected and integrated porous structure traversing the entire implant. Combined with HAFUSE sub-micron nano-texturing, the Inspire implant promotes through-growth.
Curiteva plans a full commercial release after a successful alpha launch of the Inspire TLIF Anterior and Inspire TLIF Oblique implants later this month. Additionally, the company is set to roll out alpha launches for its ALIF portfolio, encompassing Monolithic, Thoracolumbar Plate and Standalone implants later this year.
Curiteva marked the milestone of over 5,000 levels successfully treated using the Inspire Cervical implant, an increase from 2,000 procedures performed as of the end of 2024, and just two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D-printed trabecular PEEK implant. ...
Curiteva marked the milestone of over 5,000 levels successfully treated using the Inspire Cervical implant, an increase from 2,000 procedures performed as of the end of 2024, and just two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D-printed trabecular PEEK implant.
Engineered with Curiteva’s proprietary Fused Filament Fabrication 3D printers, Inspire implants feature a fully interconnected and integrated porous structure traversing the entire implant. Combined with HAFUSE sub-micron nano-texturing, the Inspire implant promotes through-growth.
Curiteva plans a full commercial release after a successful alpha launch of the Inspire TLIF Anterior and Inspire TLIF Oblique implants later this month. Additionally, the company is set to roll out alpha launches for its ALIF portfolio, encompassing Monolithic, Thoracolumbar Plate and Standalone implants later this year.
Copy to clipboard 
